Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CL316,243 is a potent and highly selective β3-adrenoceptor (beta 3 adrenergic receptor) agonist. It exhibits over 10,000-fold selectivity for the β3-adrenoceptor compared to β1 and β2 receptors. The compound increases brown adipose tissue thermogenesis and metabolic rate by stimulating lipolysis in adipocytes. These effects result in anti-obesity and anti-diabetic actions such as reduced white adipose tissue mass, decreased blood glucose and insulin levels, improved energy expenditure, and potential reduction of hypertriglyceridemia. In animal studies it has also been shown to induce muscle hypertrophy via mTOR signaling pathways. While primarily used as a research tool compound for studying metabolic diseases like obesity and diabetes mellitus type 2 (non-insulin-dependent), it is not approved for human therapeutic use[1][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CL316,243.